DK3046546T3 - Syntese og partikelmanipulation af co-krystaller - Google Patents

Syntese og partikelmanipulation af co-krystaller Download PDF

Info

Publication number
DK3046546T3
DK3046546T3 DK14772421.5T DK14772421T DK3046546T3 DK 3046546 T3 DK3046546 T3 DK 3046546T3 DK 14772421 T DK14772421 T DK 14772421T DK 3046546 T3 DK3046546 T3 DK 3046546T3
Authority
DK
Denmark
Prior art keywords
crystals
synthesis
particle manipulation
manipulation
particle
Prior art date
Application number
DK14772421.5T
Other languages
English (en)
Inventor
Iris Duarte
Maria José Pereira
Luis Padrela
Márcio Temtem
Original Assignee
Hovione Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Holding Ltd filed Critical Hovione Holding Ltd
Application granted granted Critical
Publication of DK3046546T3 publication Critical patent/DK3046546T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/0004Crystallisation cooling by heat exchange
    • B01D9/0009Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/0063Control or regulation
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B11/00Single-crystal growth by normal freezing or freezing under temperature gradient, e.g. Bridgman-Stockbarger method
    • C30B11/02Single-crystal growth by normal freezing or freezing under temperature gradient, e.g. Bridgman-Stockbarger method without using solvents
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glanulating (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK14772421.5T 2013-09-16 2014-09-16 Syntese og partikelmanipulation af co-krystaller DK3046546T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT10716613A PT107166B (pt) 2013-09-16 2013-09-16 Síntese e engenharia de partículas de cocristais
PCT/GB2014/052799 WO2015036799A1 (en) 2013-09-16 2014-09-16 Synthesis and particle engineering of cocrystals

Publications (1)

Publication Number Publication Date
DK3046546T3 true DK3046546T3 (da) 2019-05-06

Family

ID=51619215

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14772421.5T DK3046546T3 (da) 2013-09-16 2014-09-16 Syntese og partikelmanipulation af co-krystaller

Country Status (14)

Country Link
US (1) US20160228373A1 (da)
EP (1) EP3046546B1 (da)
JP (1) JP6465894B2 (da)
CN (1) CN105682644B (da)
AU (1) AU2014320095A1 (da)
CA (1) CA2923529C (da)
DK (1) DK3046546T3 (da)
ES (1) ES2717754T3 (da)
HU (1) HUE042518T2 (da)
IL (1) IL244496A0 (da)
MX (1) MX2016003212A (da)
PT (1) PT107166B (da)
SG (1) SG11201601811YA (da)
WO (1) WO2015036799A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20169994A1 (it) * 2016-01-14 2017-07-14 Phf Sa Nuove forme cristalline di farmaci immunomodulatori
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
CN108516808B (zh) * 2018-07-10 2021-03-02 哈尔滨工业大学 高温熔体气雾法制备氧化铝基纳米共晶复合微粉的方法
CN111714479B (zh) * 2019-03-23 2023-05-05 中国医学科学院药物研究所 一种含有蓓萨罗丁的药物组合物
CN111718257B (zh) * 2019-03-23 2022-11-04 中国医学科学院药物研究所 蓓萨罗丁与川芎嗪共晶物及制备方法和其组合物与用途
CN111514604B (zh) * 2020-04-17 2022-05-31 深圳大学 一种分段蒸发结晶制备高纯晶体的方法
US20230027886A1 (en) * 2021-07-20 2023-01-26 Hongjie Qiu Systems and methods for fabricating crystals of metal compounds
AU2022384750B2 (en) * 2021-09-02 2024-07-11 Cdt Equity Ltd Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1 s)-1 -methyl-2- (methyloxy)ethyl]oxy)-n-(5-methylpyrazin-2-yl)benzamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386245A1 (en) * 1999-10-06 2001-04-12 Archer-Daniels-Midland Company Co-crystallized surfactant blend
US20070031580A1 (en) * 2005-08-10 2007-02-08 Troy Boutte Solid co-crystallized monoglyceride and fatty acid lactylate emulsifier and starch-complexing agent and method of producing same
US20090024628A1 (en) * 2007-07-11 2009-01-22 United States Gypsum Company Home management, maintenance, repair, remodeling and redecoration system and method
US20100184744A1 (en) * 2007-07-18 2010-07-22 Feyecon Development & Implementation B.V. Method of preparing a pharmaceutical co-crystal composition
IN2008CH00818A (da) * 2008-04-01 2009-10-09 Actavis Group Ptc Ehf
US20100018474A1 (en) * 2008-07-25 2010-01-28 Mark Noonan Methods and adapter systems for managing slack in leashes
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
KR101566552B1 (ko) * 2009-03-13 2015-11-05 영남대학교 산학협력단 항산화, 항동맥경화 및 항당뇨 효과가 우수한 기능성 리피드
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US9250886B2 (en) * 2011-07-01 2016-02-02 International Business Machines Corporation Optimizing provisioning workflows in cloud computing

Also Published As

Publication number Publication date
SG11201601811YA (en) 2016-04-28
EP3046546B1 (en) 2019-01-02
PT107166B (pt) 2018-12-28
CA2923529A1 (en) 2015-03-19
ES2717754T3 (es) 2019-06-25
CN105682644B (zh) 2021-08-13
PT107166A (pt) 2015-03-16
WO2015036799A1 (en) 2015-03-19
AU2014320095A1 (en) 2016-03-24
HUE042518T2 (hu) 2019-07-29
MX2016003212A (es) 2016-08-08
CA2923529C (en) 2021-07-27
CN105682644A (zh) 2016-06-15
EP3046546A1 (en) 2016-07-27
IL244496A0 (en) 2016-04-21
JP2016536134A (ja) 2016-11-24
US20160228373A1 (en) 2016-08-11
JP6465894B2 (ja) 2019-02-06

Similar Documents

Publication Publication Date Title
HUS2200041I1 (hu) Anti-CD3 antitestek és alkalmazási eljárások
DK2981541T3 (da) Syntese og anvendelse af isotopmærkede glycaner
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
IL241112B (en) Methods and compositions for modification of hla
HUE045462T2 (hu) Aril-éterek és alkalmazásaik
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2968208T3 (da) Behandling af kataplexi
DK3022707T3 (da) Systemer og fremgangsmåder til at monitorere bevægelse af sygdomsfelt
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
DK2958588T3 (da) Kombination af vaccination og hæmning af PD-1-reaktionsvejen
HUE059701T2 (hu) Antitestek és felhasználási módszerek
DK2961388T3 (da) Kombinationer af lægemidler
DK3027618T3 (da) Polymorf af syk-hæmmere
DK3363805T3 (da) Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner
HRP20180684T1 (hr) Kombinacija lijekova
DK3046546T3 (da) Syntese og partikelmanipulation af co-krystaller
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3083789T3 (da) Overfladebehandling af partikler og anvendelse heraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme